Clinical trials
Phase 3 Colonic Neoplasms trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
26 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 4 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 9 |
| Unknown status | 9 |
| Active, not recruiting | 4 |
| Not yet recruiting | 2 |
| Completed | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Sun Yat-sen University | 5 |
| Fudan University | 2 |
| Pfizer | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Amgen | 1 |
| Chinese Academy of Medical Sciences | 1 |
| First Affiliated Hospital of Guangxi Medical University | 1 |
| GlaxoSmithKline | 1 |
| Haixing Ju, MD | 1 |
| Incyte Corporation | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colonic Neoplasms | 26 |
| Colorectal Neoplasms | 6 |
| Rectal Neoplasms | 6 |
| Colonic Diseases | 2 |
| Digestive System Diseases | 2 |
| Digestive System Neoplasms | 2 |
| Gastrointestinal Diseases | 2 |
| Gastrointestinal Neoplasms | 2 |
| Intestinal Diseases | 2 |
| Intestinal Neoplasms | 2 |
Trials
Showing 1 to 25 of 26. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.